Roche presents new data from multiple Phase III studies of Tecentriq in triple-negative breast cancer

Roche announced that it presented the latest results from three Phase III studies from the Tecentriq® (atezolizumab) clinical development programme in triple-negative breast cancer (TNBC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

source https://www.pharmatutor.org/pharma-news/2020/roche-presents-new-data-from-multiple-phase-iii-studies-of-tecentriq-in-triple-negative-breast-cancer